In-depth guide

UPDATED FEB 2026

Depo-Provera Settlement Amounts

Part of the Depo-Provera Brain Tumor investigation

The short answer

No Depo-Provera meningioma cases have settled or gone to trial yet. Projected settlements based on comparable pharmaceutical brain injury litigation suggest $75,000 to $1.5 million+ depending on injury severity.

People's Justice Research TeamUpdated February 20, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

Why There Are No Settlements Yet

The Depo-Provera meningioma litigation is in its early stages. The first lawsuit was filed in October 2024, and MDL 3140 was established in February 2025. Rule 702 hearings on general causation are scheduled for late May 2026. No manufacturer has made a global settlement offer.

Projected Settlement Ranges

Based on comparable pharmaceutical brain tumor and neurological injury litigation: Tier 1 (meningioma managed without surgery) projects $75,000–$200,000; Tier 2 (meningioma requiring craniotomy) projects $200,000–$600,000; Tier 3 (permanent neurological damage or recurrence) projects $600,000–$1,500,000+.

Comparable Mass Tort Settlements

The NuvaRing settlement ($100M for ~3,800 claims), Mirena IUD verdict ($12.2M individual), Elmiron vision loss bellwether verdict ($54.5M), and Depakote birth defect verdict ($15M) provide relevant benchmarks for pharmaceutical injury claims with similar failure-to-warn theories.

When Will Settlements Happen?

Settlement negotiations typically begin after bellwether trial outcomes. Rule 702 hearings in May 2026 will first determine whether plaintiffs' general causation experts can testify. If the science survives Daubert challenges, settlement pressure on Pfizer increases significantly. Filing now ensures your case is in the MDL pipeline when negotiations begin.

Key data

Data & Statistics

3 SOURCED FIGURES

2,000+

Lawsuits filed in MDL 3140

May 2026

Rule 702 hearings on general causation

5.6x

Peak meningioma risk increase (Roland et al., BMJ 2024)

Research & evidence

Scientific Evidence

Medroxyprogesterone Acetate and Meningioma: A Global Issue

Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health

View on PubMed

Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma

Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ

View on PubMed

The Association between Medroxyprogesterone Acetate Exposure and Meningioma

Griffin BR et al. (2024). Cancers

View on PubMed

FAQ

Frequently Asked Questions

37 QUESTIONS

Studies show that long-term use of Depo-Provera significantly increases the risk of meningioma — a tumor in the tissue surrounding the brain. The risk ranges from 1.5x to 5.6x depending on duration of use and the study population. Meningiomas express progesterone receptors at 60–80% rates, and the synthetic progestin in Depo-Provera (MPA) stimulates tumor growth by binding to these receptors.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Depo-Provera Brain Tumor Investigation